Advair Panel Denies Survival Benefit, But Endorses Other Efficacy Claims
FDA’s Pulmonary-Allergy Drugs Advisory Committee votes against evidence that GSK’s Advair increases survival, but agrees the combination product reduces exacerbations of COPD.
FDA’s Pulmonary-Allergy Drugs Advisory Committee votes against evidence that GSK’s Advair increases survival, but agrees the combination product reduces exacerbations of COPD.